Ainos Reports Full Year 2025 Financial Results and Highlights Commercial Momentum Entering 2026
Rhea-AI Summary
Ainos (NASDAQ:AIMD) reported 2025 results showing ~499% revenue growth and a swing to positive gross margin of 82.9%. The company secured a New Taiwan Dollar 90 million financing (~USD $2.82M) and announced early 2026 semiconductor deployments: ~200 front-end systems and 1,400 systems under a three-year $2.1M program with deposits received and a roadmap to 20,000 systems.
Management emphasized scaled AI Nose commercial deployments, recurring Smell ID and Smell Language Model monetization, and disciplined capital allocation entering 2026.
Positive
- Revenue +499% YoY in 2025
- Gross margin 82.9% in 2025 (positive vs. 2024 gross loss)
- 1,400-system, three-year $2.1M deployment with deposits received and roadmap to 20,000 systems
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AIMD showed a modest pre-news gain of 0.72%, while momentum peers were mixed: NVNO up 3.87%, but XAIR and ADGM down around 3.1–3.3%, pointing to stock-specific drivers rather than a uniform sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Q3 2025 earnings | Positive | -14.3% | Q3 2025 results with AI Nose scale-up, more partnerships, and lower expenses. |
| Aug 13 | Q2 2025 earnings | Positive | +13.7% | Q2 2025 results with first $2.1M subscription and strong AI Nose accuracy. |
| May 12 | Q1 2025 earnings | Positive | +1.9% | Q1 2025 revenue up 412% YoY and swing to gross profit on AI Nose. |
| Mar 07 | FY 2024 earnings | Negative | -5.9% | FY 2024 revenue decline and larger net loss despite program advances. |
| Nov 13 | 3Q24 & trial note | Positive | -1.2% | IRB approval for VELDONA trial and sufficient cash commentary. |
Earnings updates have produced volatile and often mixed reactions, with several broadly positive reports followed by negative next-day moves.
Over the past five earnings-related updates from Nov 2024 through Nov 2025, Ainos emphasized scaling its AI Nose platform, expanding partnerships, and exercising cost discipline. Q1–Q3 2025 featured strong revenue growth, margin improvement, and new multi-year semiconductor subscriptions, while full-year 2024 results highlighted a strategic shift away from COVID-19 testing despite weaker revenue and higher net loss. Today’s full-year 2025 results continue this trajectory of AI Nose–driven growth and industrial commercialization.
Historical Comparison
In the past five earnings-tagged events, AIMD’s average next-day move was -1.17%, showing choppy reactions. Today’s modest pre-news gain of 0.72% sits well within that historical range.
Earnings updates trace a shift from FY 2024’s weaker COVID-era revenues toward 2025’s AI Nose-driven growth, cost discipline, and expanding industrial and semiconductor partnerships.
Market Pulse Summary
This announcement highlights Ainos’ 2025 inflection, with AI Nose driving 499% revenue growth, gross margin improving to 82.9%, and operating expenses ex‑noncash items down 9%. The company also added about NT$90M (≈$2.82M) in financing and detailed semiconductor deployments of ~200 and 1,400 systems. Investors may track conversion toward the up-to-20,000-system roadmap, margin sustainability, and future earnings updates for confirmation of deployment-driven scale.
Key Terms
gross margin financial
AI-generated analysis. Not financial advice.
AI Nose drove
2025 partnerships now driving scaled AI Nose deployments in 2026, supported by disciplined financing
HOUSTON, TX / ACCESS Newswire / March 30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today reported financial results for the year ended December 31, 2025 and outlined commercialization momentum entering 2026.
During 2025, Ainos expanded its industrial ecosystem of AI Nose platform across semiconductor, smart factory, robotics, and industrial AI environments, establishing the foundation for deployment-driven growth. AI Nose deployments combine hardware sensing with recurring software and data monetization through Smell IDand the Smell Language Model (SLM).
"2025 marked our transition in expanding AI Nose's commercial focus from healthcare into industrial markets. Our focus in 2025 was building the platform and partnerships required for scale," said Eddy Tsai, Chairman and CEO of Ainos. "As we enter 2026, that groundwork is translating into operational momentum, with early AI Nose deployments underway, particularly in semiconductor environments. As deployments expand, AI Nose generates Smell ID data that continuously trains our SLM, reinforcing our long-term data advantage."
"In 2025 we maintained a disciplined financial approach while supporting SmellTech platform's scale. Total revenue increased approximately
"Subsequent to year-end, we strengthened our financial position through a New Taiwan
Semiconductor Deployment Scaling Gains Momentum in 2026
In 2026, Ainos has launched early-stage deployments of AI Nose systems across semiconductor environments, including:
~200 systems for deployment in front-end wafer fabrication facilities targeted for 1Q 2026 for technical validation, supporting potential commercial integration.
~1,400 systems under a three-year
$2.1 million deployment in semiconductor packaging and testing environments, targeted for completion in Q2 2026, with deposits received, and a roadmap contemplated to scale to up to 20,000 systems, subject to validation and contractual conversion.
These deployments aim to support system integration and real-world data generation in demanding semiconductor environments, serve as a foundation for scaled commercial rollout and revenue activation over time.
"We believe scent intelligence represents a new perception layer for artificial intelligence in the physical world, enabling machines to interpret environmental signals that previously could not be digitized," Mr. Tsai concluded.
About AI Nose
AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.
Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI Nose is offered under a SmellTech-as-a-Service architecture, intended to support ongoing access to scent intelligence, analytics, and AI-driven insights through subscription-based deployment models.
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Investor Relations
ir@ainos.com
Ainos, Inc.
Consolidated Balance Sheets
December 31, | ||||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 417,353 | $ | 3,892,919 | ||||
Accounts receivable | 22 | 56 | ||||||
Inventory, net | 295,565 | 143,756 | ||||||
Other current assets | 425,859 | 301,077 | ||||||
Total current assets | 1,138,799 | 4,337,808 | ||||||
Intangible assets, net | 19,226,003 | 23,748,328 | ||||||
Property and equipment, net | 343,281 | 559,645 | ||||||
Other assets | 163,025 | 174,418 | ||||||
Total assets | $ | 20,871,108 | $ | 28,820,199 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Contract liabilities | $ | 350,000 | $ | 106,329 | ||||
Convertible notes payable | - | 3,000,000 | ||||||
Accrued expenses and other current liabilities | 728,683 | 848,615 | ||||||
Total current liabilities | 1,078,683 | 3,954,944 | ||||||
Convertible notes payable - noncurrent | 11,000,000 | 9,000,000 | ||||||
Other long-term liabilities | 1,229,843 | 348,945 | ||||||
Total liabilities | 13,308,526 | 13,303,889 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | 69,827 | 30,854 | ||||||
Treasury stock, at cost (1,160,000 and nil shares held as of December 31, 2025 and 2024, respectively) | (1,972,000 | ) | - | |||||
Additional paid-in capital | 77,234,374 | 68,644,301 | ||||||
Accumulated deficit | (67,520,328 | ) | (52,749,316 | ) | ||||
Accumulated other comprehensive loss - translation adjustment | (249,291 | ) | (409,529 | ) | ||||
Total stockholders' equity | 7,562,582 | 15,516,310 | ||||||
Total liabilities and stockholders' equity | $ | 20,871,108 | $ | 28,820,199 | ||||
Ainos, Inc.
Consolidated Statements of Operations
Years ended December 31, | ||||||||
2025 | 2024 | |||||||
Revenues | $ | 124,157 | $ | 20,729 | ||||
Cost of revenues | (21,246 | ) | (52,595 | ) | ||||
Gross profit (loss) | 102,911 | (31,866 | ) | |||||
Operating expenses: | ||||||||
Research and development expenses | 7,749,772 | 8,413,923 | ||||||
Selling, general and administrative expenses | 6,343,547 | 5,395,415 | ||||||
Total operating expenses | 14,093,319 | 13,809,338 | ||||||
Loss from operations | (13,990,408 | ) | (13,841,204 | ) | ||||
Non-operating income (expenses), net | ||||||||
Interest expense | (711,903 | ) | (616,467 | ) | ||||
Issuance cost of senior secured convertible note measured at fair value | - | (308,336 | ) | |||||
Fair value change of senior secured convertible note | - | (275,624 | ) | |||||
Other income (expenses), net | (67,901 | ) | 179,270 | |||||
Total non-operating expenses, net | (779,804 | ) | (1,021,157 | ) | ||||
Net loss before income taxes | (14,770,212 | ) | (14,862,361 | ) | ||||
Provision for income taxes | 800 | 800 | ||||||
Net loss | $ | (14,771,012 | ) | $ | (14,863,161 | ) | ||
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
How much did Ainos (AIMD) grow revenue in 2025 and what drove it?
What was Ainos's gross margin in 2025 and how did it change from 2024?
What semiconductor deployments did Ainos (AIMD) announce for 2026?
How much financing did Ainos (AIMD) secure after year-end and why does it matter?
What is Ainos's commercial model for AI Nose and revenue sources?
Did Ainos report changes in operating expenses for 2025 (AIMD)?
